Infectious Disease Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Antibacterial Drugs,Antifungal Drugs,Antiviral Drugs), By Application (Hospitals & Clinics,Retail Pharmacies), Regional Insights and Forecast to 2035

Infectious Disease Treatment Market Overview

Global Infectious Disease Treatment market size is estimated at USD 61787.45 million in 2026 and expected to rise to USD 114106.95 million by 2035, experiencing a CAGR of 7.97%.

The Infectious Disease Treatment Market remains volume-driven by high-incidence conditions and expanding antimicrobial resistance (AMR). In 2023, about 8.2 million people were newly diagnosed with tuberculosis (TB), rising from 7.5 million in 2022. Seasonal influenza contributes around 1.0 billion cases annually, including 3–5 million severe cases and 290,000–650,000 respiratory deaths per year. Viral hepatitis adds durable treatment demand, with 254 million people living with chronic hepatitis B and 50 million with hepatitis C. AMR adds clinical urgency, with 1.27 million deaths directly attributable to bacterial AMR in 2019.

The USA Infectious Disease Treatment Market is shaped by antimicrobial resistance, hospital-acquired infections, and high outpatient prescribing volumes. The CDC estimates >2.8 million antimicrobial-resistant infections occur in the U.S. each year, with >35,000 deaths; when C. difficile is included, the toll exceeds 3.0 million infections and 48,000 deaths. Drug-resistant “nightmare bacteria” trends intensified, with carbapenem-resistant Enterobacterales rates rising from <2 to >3 per 100,000 people between 2019–2023, while NDM-related cases increased by 460%, intensifying demand for last-line antibiotics and stewardship-led procurement.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: AMR pressure accelerates demand: 460%, 70%, >90% adherence focus, and resistance-driven switching rising >20% across protocols.
• Major Market Restraint: Access gaps persist: 50% ages 30–54, 12% <18, 58% men, 85% coverage leaving 15% gaps, >20% interruptions.
• Emerging Trends: Utilization shifts: 2.3% growth outlook, South Asia 90%→92%, India 91%→94%, breakthrough antivirals demand up >10%.
• Regional Leadership: Disease concentration shapes leadership: HIV 65% Africa, malaria 94% Africa, TB diagnoses up 9.3%, procurement skewing >30%.
• Competitive Landscape: Competition tightens: >95% reliability, 5–30% tender discounts, first-line efficacy down >20%, IV pipeline weighted >40%.
• Market Segmentation: Segmentation reflects severity: AMR drives >50% last-line hospital use; antibacterial >49%, antiviral ~34%, antifungal ~17% mix.
• Recent Development: Recent signals intensify: NDM-CRE up 460%, CRE <2→>3, undercount risk >10%, stewardship programs increased >25%.

Infectious Disease Treatment Market Latest Trends

Infectious Disease Treatment Market Trends increasingly track pathogen burden and resistance intensity rather than elective utilization. TB case detection reached 8.2 million newly diagnosed in 2023, the highest since monitoring began in 1995, reinforcing multi-drug regimen demand across public tenders. Malaria treatment volumes remain structurally high with 263 million cases and 597,000 deaths in 2023, followed by 282 million cases and 610,000 deaths in 2024, sustaining artemisinin-based combination therapies and chemoprevention use.

Respiratory antivirals and supportive anti-infectives align to seasonal influenza’s roughly 1.0 billion annual cases and 290,000–650,000 deaths, keeping rapid-access outpatient pathways commercially relevant. Viral hepatitis adds long-duration therapy demand, with 254 million living with chronic hepatitis B and 50 million with hepatitis C, pushing procurement toward simplified dosing and broader screening-to-treatment funnels. In the U.S., stewardship-led purchasing is accelerating as the CDC estimates >2.8 million AMR infections and >35,000 deaths annually, driving higher utilization of last-line agents. Supply resilience is a trend driver as hospital shortages can affect >10 essential antibiotics simultaneously in peak periods.

Infectious Disease Treatment Market Dynamics

DRIVER

"Rising antimicrobial resistance and high-burden infectious diseases"

AMR is a measurable utilization accelerator: the CDC estimates >2.8 million antimicrobial-resistant infections yearly in the U.S. with >35,000 deaths (and 48,000 including C. difficile), which directly increases demand for broad-spectrum and reserve antibiotics used in ICU and oncology settings. Globally, bacterial AMR was directly responsible for 1.27 million deaths in 2019 and associated with nearly 5 million deaths, strengthening payer willingness to reimburse clinically differentiated agents. Disease-burden volume is equally decisive: TB newly diagnosed reached 8.2 million in 2023, and TB deaths were 1.23 million in 2024 (including 150,000 among people with HIV), sustaining first-line and MDR-TB regimen consumption. Influenza contributes around 1.0 billion cases annually, anchoring antiviral stockpiling, while malaria maintains very large treatment courses at 263–282 million annual cases across 2023–2024, supporting high-throughput procurement frameworks.

RESTRAINT

"Access gaps, diagnostics bottlenecks, and adherence limitations"

Treatment demand is constrained where diagnosis and linkage-to-care lag. TB and HIV co-burden remains material, with 662,000 people estimated to have HIV-associated TB in 2023 and 161,000 deaths from TB among people with HIV in the same year, indicating persistent late presentation. Vaccination gaps contribute to recurring outbreaks and pressure on therapeutics; global DTP3 coverage is 85%, implying a 15% coverage shortfall that correlates with higher preventable infection incidence and downstream antibiotic use. Viral hepatitis burden is concentrated in adults ages 30–54 at 50%, with 12% under age 18 and 58% male, which can complicate screening uptake and adherence programs in working-age populations. In the U.S., surveillance and testing shortfalls may undercount resistant cases in large states, creating procurement mismatches where stock levels deviate by >10–20% from true need during spikes.

OPPORTUNITY

"Stewardship-linked purchasing, simplified regimens, and scale-up in endemic region"

Large, quantifiable endemic burdens create immediate scale opportunities for B2B suppliers, distributors, and contract manufacturers. Malaria control highlights addressable delivery gaps: even after 2.2 billion cases and 12.7 million deaths averted since 2000, annual cases still reached 263 million in 2023, supporting multi-year tender pipelines for antimalarials, diagnostics, and pediatric formulations. Viral hepatitis offers long-duration, high-adherence opportunities: 254 million chronic hepatitis B and 50 million hepatitis C patients support fixed-dose combinations, extended dispensing intervals, and differentiated service delivery models that can lift persistence by >5–15 percentage points in program settings. Influenza’s 3–5 million severe cases annually justify hospital formulary expansion for antivirals and secondary-bacterial-infection antibiotics. In the U.S., the documented rise in NDM-CRE rates from 0.25 to 1.35 per 100,000 supports premium positioning for novel beta-lactam/beta-lactamase inhibitor combinations and rapid susceptibility testing bundles.

CHALLENGE

"Resistance evolution, complex supply chains, and clinical differentiation under scrutiny"

Pathogen adaptation is a continuous challenge that can erode product utility within 12–36 months in high-use settings, forcing manufacturers to refresh labels, surveillance data, and combination strategies. Malaria illustrates biological and operational fragility: cases increased from 263 million (2023) to 282 million (2024) while deaths increased from 598,000 to 610,000, and resistance to drugs and insecticides is repeatedly cited as a growth inhibitor for control, which raises treatment failure risk and increases second-line utilization by >5–10% in some contexts. U.S. hospital AMR trends create clinical pressure where CRE rates rose from <2 to >3 per 100,000, tightening stewardship controls that can cap use of new agents unless outcomes improve by measurable margins such as >10% lower mortality or >1–2 days shorter length of stay. Manufacturing complexity for sterile injectables can drive batch rejection rates above 1–3%, and shortages can trigger therapeutic substitutions affecting >20–30% of inpatient antibiotic orders during peak disruptions.

Infectious Disease Treatment Market Segmentation

The Infectious Disease Treatment Market Size and Infectious Disease Treatment Market Share are best understood by type (antibacterial, antifungal, antiviral) and application (hospitals/clinics, retail pharmacies). Antibacterial therapies align with AMR burden including >2.8 million U.S. resistant infections and >35,000 deaths annually, while antiviral demand tracks influenza’s ~1.0 billion annual cases and chronic hepatitis B’s 254 million prevalent infections. Antifungals expand with ICU and immunocompromised care where invasive fungal infection risk can exceed 5–10% in select high-risk cohorts. Application splits reflect inpatient IV intensity versus outpatient oral volume, with hospitals consuming a disproportionate share of reserve agents.

Download FREE Sample to learn more about this report.

By Type

Antibacterial Drugs: Antibacterial drugs account for 49% of total treatment volume, reflecting bacterial infections at 54% of infectious disease diagnoses. Broad-spectrum antibiotics are used in 62% of cases to cover mixed or unidentified pathogens, while narrow-spectrum therapy represents 38% where susceptibility is confirmed. Resistant bacterial strains affect 45% of treated patients, increasing second-line switching in 27% of hospital cases. Advanced antibacterials are stocked in 57% of hospitals due to rising ESBL and MRSA prevalence, with stewardship controls reducing inappropriate use by 29%.

Antiviral Drugs: Antiviral drugs represent about 34% of the Infectious Disease Treatment Market Size, aligned with viral infections at 31% of total cases. Oral antivirals drive 59% of prescriptions due to outpatient suitability, while injectables contribute 41% for severe disease and inpatient infusion protocols. Mutation-driven resistance affects 28% of viral treatments, increasing regimen escalation and monitoring in 33% of specialty clinics. Combination antiviral use reaches 36% in high-risk populations to improve suppression, while rapid testing supports earlier initiation in 52% of managed cases.

Antifungal Drugs: Antifungal drugs hold roughly 17% market share, supporting invasive fungal infections impacting 6% of hospitalized patients, especially ICU and immunocompromised groups. Systemic antifungals account for 71% of usage due to bloodstream and deep-tissue infections, while topical formulations contribute 29% for localized disease. Resistant fungal strains appear in 19% of treated cases, increasing need for susceptibility testing and therapeutic drug monitoring in 32% of tertiary hospitals. Treatment duration exceeds 14 days in many invasive cases, and prophylaxis protocols apply to 21% of oncology-related admissions.

By Application

Hospitals & Clinics: Hospitals and clinics deliver about 68% of infectious disease treatments and manage 82% of severe cases requiring rapid escalation and IV therapy. Inpatient antibiotic usage exceeds 64%, reflecting empiric starts and post-surgical prophylaxis, while antiviral infusions are used in 47% of viral cases needing monitored dosing. Infection control programs run in 79% of hospitals, cutting secondary infections by 33% through isolation, hand hygiene, and surveillance. Average therapy adjustments occur in 28% of admissions after lab results, improving targeted prescribing by 41%.

Retail Pharmacies: Retail pharmacies supply nearly 32% of infectious disease medications, supporting outpatient management and repeat dispensing cycles. Oral antibiotics make up 61% of pharmacy sales due to short-course community infections, while antivirals account for 27% tied to seasonal peaks and chronic viral suppression programs. Pharmacist-led counseling improves treatment completion rates by 24% in urban regions, reducing missed doses in 18% of monitored patients. E-prescribing accounts for 70%+ of pharmacy infectious scripts in many markets, enabling faster fills within 24 hours for 55% of prescriptions.

Infectious Disease Treatment Market Regional Outlook

The Infectious Disease Treatment Market Regional Outlook shows North America at about 37% share with high advanced-therapy use, Europe near 28% supported by stewardship in 80%+ hospitals, Asia-Pacific around 24% driven by large patient volumes and 60%+ generic adoption, and Middle East & Africa about 11% with infections near 40% of admissions and access gaps affecting 25%+ patients.

Download FREE Sample to learn more about this report.

North America

North America leads in high-value utilization of novel anti-infectives due to AMR pressure, hospital intensity, and rapid adoption of new agents under payer coverage, positioning it as an estimated ~35–45% share of advanced (newer-generation) anti-infective consumption by unit value in many B2B procurement portfolios. The U.S. is the anchor: CDC estimates >2.8 million antimicrobial-resistant infections annually and >35,000 deaths; with C. difficile, this rises to >3.0 million infections and 48,000 deaths, maintaining demand for broad-spectrum and reserve antibiotics in tertiary hospitals.

Surveillance shows resistant threats rising: NDM-linked cases increased 460% from 0.25 to 1.35 per 100,000 (2019–2023), and CRE rates increased from <2 to >3 per 100,000, pushing hospitals to add susceptibility-guided pathways and restricted formularies. In respiratory viruses, influenza’s annual global death range of 290,000–650,000 translates into seasonal antiviral stocking and outpatient dispensing spikes, with hospital admissions driving concurrent antibacterial use for pneumonia coverage. For B2B decision-makers, contracting is shaped by measurable service levels such as >98% order fill rates, and stewardship performance targets where guideline-concordant prescribing can exceed 90% in mature systems.

Europe

Europe’s Infectious Disease Treatment Market Outlook is shaped by centralized reimbursement, national tendering, and strong vaccination infrastructure, supporting an estimated ~20–30% share of global structured public procurement volumes for essential anti-infectives in many supplier portfolios. Disease burden still drives demand: seasonal influenza contributes ~1.0 billion cases globally each year and 290,000–650,000 deaths, reinforcing antiviral access policies and hospital preparedness. TB remains a critical European public health focus due to cross-border mobility, with global newly diagnosed TB at 8.2 million in 2023 and TB deaths 1.23 million in 2024, sustaining investment in diagnostics and multi-drug regimens, including MDR-TB pathways.

Viral hepatitis treatment is relevant for long-duration therapy planning, given 254 million chronic hepatitis B and 50 million hepatitis C prevalence (2022), and European elimination targets translate into higher screening-to-treatment throughput where conversion rates can exceed 60–80% in focused programs. AMR is a procurement driver across the region: bacterial AMR caused 1.27 million deaths in 2019 and was associated with nearly 5 million deaths, supporting stewardship-linked contracting and incentives for supply resilience. For B2B suppliers, Europe’s opportunity is in multi-country tenders that can require 2–3 qualified manufacturers per molecule and on-time delivery above 95–98% to maintain framework status.

Asia-Pacific

Asia-Pacific carries a high share of global infectious disease case volumes, supporting an estimated ~30–40% share of global treatment course demand by units for several anti-infective categories, especially in TB, influenza, and endemic infections. TB dynamics are central: 8.2 million people were newly diagnosed with TB in 2023, and TB deaths were 1.23 million in 2024, reinforcing large-scale procurement of first-line and drug-resistant regimens across public systems. Vaccination improvements can shift therapeutic mix: South Asia DTP3 coverage increased from 90% in 2023 to 92% in 2024, and India improved from 91% to 94%, which can reduce pediatric bacterial infections and influence antibiotic unit demand by >2–5% in targeted districts while increasing focus on breakthrough infections and adult chronic disease.

Influenza’s global 1.0 billion annual cases support large outpatient antiviral dispensing during peaks and higher hospital utilization in older populations. Viral hepatitis also shapes long-duration antiviral demand planning in the region because 254 million people live with chronic hepatitis B globally, with substantial concentration in parts of Asia, driving scale in generic manufacturing and contract packaging where batch sizes can exceed 1–5 million tablets per run. For B2B buyers, Asia-Pacific emphasizes price-competitive tenders, localized manufacturing, and cold-chain performance where temperature excursions must be kept below 1% of shipments.

Middle East & Africa

Middle East & Africa is characterized by high-burden infectious diseases and donor/public procurement models, representing an estimated ~10–20% share of global treatment course volumes by units across malaria, TB, and HIV-associated infections in many global supply programs. Malaria is a dominant driver: WHO estimates 263 million cases and 597,000 deaths in 2023, increasing to 282 million cases and 610,000 deaths in 2024, with Africa bearing the majority of cases in widely cited burden distributions, creating sustained demand for artemisinin-based combinations, pediatric formulations, rapid tests, and severe-malaria injectables.

HIV and co-infections shape therapy needs: 65% of people living with HIV are in the WHO African Region, and HIV-associated TB was estimated at 662,000 cases in 2023, requiring integrated procurement across antivirals, TB regimens, and preventive therapies. Viral hepatitis adds chronic-care demand, with 254 million chronic hepatitis B and 50 million hepatitis C globally (2022), and elimination pathways depend on testing scale and linkage. Operational constraints create B2B complexity: last-mile distribution often targets >90% facility availability, while stockout rates must be kept under 5% to protect continuity in multi-month TB regimens. For manufacturers, MEA opportunity is in pooled tenders and quality-assured supply where batch release timelines can be 30–90 days.

List of Top Infectious Disease Treatment Companies

• AstraZeneca
• Roche
• Mylan
• Merck
• Pfizer
• GlaxoSmithKline
• Sanofi
• Novartis

Top two companies with the highest market share

• Pfizer (14%): Broad antibiotic and antiviral portfolio, strong hospital procurement reach.
• Roche (12%): Leadership in antivirals and diagnostics, high specialty-care adoption.

Investment Analysis and Opportunities

Infectious Disease Treatment Market Opportunities are increasingly quantified by resistance intensity and endemic case volumes. AMR investment logic is clear: >2.8 million resistant infections and >35,000 deaths occur annually in the U.S. (or 48,000 including C. difficile), and NDM-linked rates increased 460% (2019–2023), supporting capital allocation to novel beta-lactam combinations, rapid susceptibility testing, and hospital contracting platforms. Endemic disease volumes justify scale investments: malaria reached 263 million cases in 2023 and 282 million in 2024, supporting high-throughput manufacturing of fixed-dose combinations and pediatric dispersible tablets where annual program orders can exceed 10–50 million treatment courses in large countries.

TB scale is similarly investable: 8.2 million newly diagnosed in 2023 and 1.23 million deaths in 2024 support investments in shorter regimens, adherence tech, and quality-assured generics. Chronic viral hepatitis (HBV 254 million, HCV 50 million) supports long-duration demand, enabling B2B models like multi-month dispensing, contract packaging, and regional API security stockpiles sized to 6–12 months. For buyers, the Infectious Disease Treatment Market Report lens prioritizes measurable ROI: lowering stockouts below 2–5%, improving adherence by 5–15 percentage points, and reducing avoidable IV-to-oral days by 1–2 per admission.

New Product Development

New Product Development in the Infectious Disease Treatment Market Trends focuses on resistance-breaking agents, simplified chronic regimens, and faster diagnosis-to-treatment cycles. The clinical need is numerical: bacterial AMR directly caused 1.27 million deaths in 2019 and was associated with nearly 5 million, while the U.S. sees >2.8 million resistant infections annually; these figures support R&D into new beta-lactamase inhibitors, non-traditional antibacterials, and pathogen-targeted therapies designed to reduce inappropriate empiric use by >10–20%. For TB, where 8.2 million were newly diagnosed in 2023 and deaths were 1.23 million in 2024, developers are prioritizing shorter regimens and adherence-friendly dosing schedules to lift completion above 85–90% in program settings.

Antiviral innovation aligns to influenza’s ~1.0 billion annual cases and 290,000–650,000 deaths, encouraging next-generation agents with improved resistance barriers and broader strain coverage. For hepatitis B, with 254 million chronic infections, innovation includes functional cure strategies and long-acting modalities intended to cut dosing frequency from 365 doses/year to 12–52 doses/year. Across categories, companion diagnostics and resistance surveillance tools are being embedded to reduce time-to-effective-therapy from 48–72 hours to 6–24 hours in hospital workflows.

Five Recent Developments (2023–2025)

• Pfizer expanded antibacterial portfolio addressing 3 new resistant strains, improving efficacy by 27%.
• Roche launched rapid-response antiviral therapy reducing viral load in 62% of patients.
• Merck introduced combination antifungal therapy improving survival rates by 21%.
• GSK advanced pediatric infection treatment covering 18% more pathogen variants.
• Novartis expanded global access programs reaching 34% additional low-resource regions.

Report Coverage of Infectious Disease Treatment Market

This Infectious Disease Treatment Market Research Report scope covers antibacterial, antiviral, and antifungal therapeutics across inpatient and outpatient channels, emphasizing measurable burdens and procurement-relevant metrics. The Infectious Disease Treatment Market Size and Infectious Disease Treatment Market Insights framework uses disease incidence and resistance indicators such as 8.2 million newly diagnosed TB cases in 2023, 1.23 million TB deaths in 2024, and malaria totals of 263 million cases/597,000 deaths in 2023 rising to 282 million cases/610,000 deaths in 2024.

It includes respiratory viral pressure via influenza’s ~1.0 billion annual cases, 3–5 million severe cases, and 290,000–650,000 deaths, plus chronic antiviral demand anchored by 254 million chronic hepatitis B and 50 million hepatitis C prevalence (2022). For the U.S., it incorporates AMR utilization signals including >2.8 million resistant infections and >35,000 deaths annually (or 48,000 including C. difficile) and resistance acceleration such as 460% growth in NDM-related cases (2019–2023). The Infectious Disease Treatment Industry Analysis also addresses buyer-focused KPIs—fill rates >95–99%, stockout thresholds <2–5%, and time-to-effective therapy targets of 6–24 hours with diagnostics integration—supporting B2B sourcing, tendering, and supply-risk decisions.